Synonym
L 659837; L-659837; L659837; L-659,837 L 659,837; L659,837;
IUPAC/Chemical Name
(S)-N1-((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-oxo-3-phenylpropan-2-yl)amino)propan-2-yl)-2-((S,Z)-2-((S)-2-((R)-3-amino-2-oxopyrrolidin-1-yl)-4-methylpentanamido)-4-(methylthio)but-3-enamido)pentanediamide
InChi Key
UXGOMHKZXISRJP-JSEVQACXSA-N
InChi Code
1S/C40H52N8O7S/c1-24(2)19-34(48-17-15-29(41)40(48)55)39(54)46-32(16-18-56-3)37(52)45-31(13-14-35(42)50)36(51)47-33(21-26-22-43-30-12-8-7-11-28(26)30)38(53)44-27(23-49)20-25-9-5-4-6-10-25/h4-12,16,18,22-24,27,29,31-34,43H,13-15,17,19-21,41H2,1-3H3,(H2,42,50)(H,44,53)(H,45,52)(H,46,54)(H,47,51)/b18-16-/t27-,29+,31-,32-,33-,34-/m0/s1
SMILES Code
CC(C)C[C@H](N1C([C@H](N)CC1)=O)C(N[C@@H](/C=C\SC)C(N[C@@H](CCC(N)=O)C(N[C@@H](Cc(c[nH]2)c3c2cccc3)C(N[C@@H](Cc4ccccc4)C=O)=O)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
788.96
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Palea S, Corsi M, Artibani W, Ostardo E, Pietra C. Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther. 1996 May;277(2):700-5. PubMed PMID: 8627548.
2: Corsi M, Palea S, Pietra C, Oliosi B, Gaviraghi G, Sugg E, Van Amsterdam FT, Trist DG. A further analysis of the contraction induced by activation of cholecystokinin A receptors in guinea pig isolated ileum longitudinal muscle-myenteric plexus. J Pharmacol Exp Ther. 1994 Aug;270(2):734-40. PubMed PMID: 7520941.
3: Kunitomo M, Imaizumi N, Sameshima E, Fujiwara M. Pharmacological analysis of receptors involved in tachykininergic contraction induced by electrical transmural stimulation in the rabbit iris sphincter muscle. Regul Pept. 1993 Jul 2;46(1-2):282-4. PubMed PMID: 7692516.
4: McKnight AT, Maguire JJ, Elliott NJ, Fletcher AE, Foster AC, Tridgett R, Williams BJ, Longmore J, Iversen LL. Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors. Br J Pharmacol. 1991 Oct;104(2):355-60. PubMed PMID: 1665732; PubMed Central PMCID: PMC1908569.
